Skip to content
OpenCapital
Get started

Arbutus Biopharma Corporation ABUS Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

AbbVie logo
AbbVieABBV
——
Beam Therapeutics logo
Beam TherapeuticsBEAM
——

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×—
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's contingent consideration fair value adjustments?
Arbutus Biopharma Corporation (ABUS) reported contingent consideration fair value adjustments of $209K in Q1 2026.
How has Arbutus Biopharma Corporation's contingent consideration fair value adjustments changed year-over-year?
Arbutus Biopharma Corporation's contingent consideration fair value adjustments decreased by 30.1% year-over-year, from $299K to $209K.
What is the long-term trend for Arbutus Biopharma Corporation's contingent consideration fair value adjustments?
Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's contingent consideration fair value adjustments has grown at a -0.6% compound annual growth rate (CAGR), from $1.87M to -$1.83M.